DeepMed Research

Ashvattha Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Phase 1

Recruiting

Conditions: Multiple Sclerosis (MS)
Parkinson Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Alzheimer Disease (AD)

Interventions: Drug: 18F-OP-801

First Posted Date: 2022-05-27

Last Posted Date: 2025-05-02

Lead Sponsor: Ashvattha Therapeutics, Inc.

Target Recruit Count: 65

Registration Number: NCT05395624

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
UCSF, San Francisco, California, United States

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

Phase 2

Active, not recruiting

Conditions: Neovascular Age-related Macular Degeneration
Diabetic Macular Edema

Interventions: Drug: D-4517.2

First Posted Date: 2022-05-24

Last Posted Date: 2025-05-04

Lead Sponsor: Ashvattha Therapeutics, Inc.

Target Recruit Count: 50

Registration Number: NCT05387837

Locations: 🇺🇸
Envision Ocular, LLC, Bloomfield, New Jersey, United States
🇺🇸
Macro Trials, Los Angeles, California, United States
🇺🇸
University Retina - Lemont, Lemont, Illinois, United States

and more 13 locations

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

Phase 1

Completed

Conditions: Diabetic Macular Edema
Neovascular Age-related Macular Degeneration

Interventions: Drug: D-4517.2

First Posted Date: 2021-11-03

Last Posted Date: 2022-09-21

Lead Sponsor: Ashvattha Therapeutics, Inc.

Target Recruit Count: 16

Registration Number: NCT05105607

Locations: 🇦🇺
Nucleus Network (Brisbane), Brisbane, Queensland, Australia

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: OP-101
Drug: Placebo

First Posted Date: 2020-07-07

Last Posted Date: 2023-02-13

Lead Sponsor: Ashvattha Therapeutics, Inc.

Target Recruit Count: 28

Registration Number: NCT04458298

Locations: 🇺🇸
Research Site, Houston, Texas, United States
🇺🇸
Research site, Baltimore, Maryland, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy